Chimeric Antigen Receptor Therapy

Carl H. June(Memorial Sloan Kettering Cancer Center), Michel Sadelain(Memorial Sloan Kettering Cancer Center)
New England Journal of Medicine
July 4, 2018
Cited by 2,245Open Access
Full Text

Abstract

Interview with Dr. Carl June on chimeric antigen receptor therapy. (09:04)Download This review addresses T-cell engineering and synthetic immunity, with a focus on producing durable remissions in patients with treatment-refractory tumors. Toxic effects of chimeric antigen receptor therapies include cytokine release syndrome and neurologic dysfunction.


Related Papers

No related papers found

Powered by citation graph analysis